{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T07:38:31Z","timestamp":1769845111161,"version":"3.49.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T00:00:00Z","timestamp":1580169600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T00:00:00Z","timestamp":1580169600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Ambrisentan is a selective endothelin receptor antagonist used for the treatment of pulmonary arterial hypertension (PAH). Little is known about ambrisentan removal by hemodialysis in patients with end-stage renal disease (ESRD).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>A 53-year-old woman with HIV\/hepatitis C virus (HCV) co-infection, PAH and ESRD on regular hemodialyis was admitted in our hospital due to refractory heart failure while on treatment with bosentan (125\u2009mg twice daily) and tadalafil (20\u2009mg once daily) for PAH and antiretroviral treatment (cART) including darunavir\/cobicistat (800\/150\u2009mg once daily). Excessive exposure to bosentan due to drug interactions between bosentan and darunavir\/cobicistat was suspected. Bosentan was replaced by ambrisentan, with progressive improvement in her clinical condition. Pre- and postdialyzer cocentrations of ambrisentan in plasma were determined and hemodialysis extraction ratio for ambrisentan was 2%.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Our results suggest that hemodialysis results in minimal ambrisentan removal, and therefore no specific ambrisentan dosage adjustment seems to be required in ESRD patients undergoing hemodialysis.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12882-019-1659-5","type":"journal-article","created":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T00:29:18Z","timestamp":1580257758000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Ambrisentan use in a HIV-1 infected patient with end-stage renal disease and pulmonary hypertension: minimal removal by hemodialysis - a case report"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0886-7114","authenticated-orcid":false,"given":"Jos\u00e9 Ram\u00f3n","family":"Santos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Merino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter E.","family":"Haefeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marisol","family":"Prats","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioana","family":"Bancu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda","family":"Bail\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Molt\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,28]]},"reference":[{"issue":"3","key":"1659_CR1","doi-asserted-by":"publisher","first-page":"388","DOI":"10.5527\/wjn.v4.i3.388","volume":"4","author":"M Ando","year":"2015","unstructured":"Ando M, Yanagisawa N. Epidemiology, clinical characteristics, and management of chronic kidney disease in human immunodeficiency virus-infected patients. World J Nephrol. 2015;4(3):388\u201395.","journal-title":"World J Nephrol"},{"issue":"4","key":"1659_CR2","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1097\/COH.0000000000000067","volume":"9","author":"GN Nadkarni","year":"2014","unstructured":"Nadkarni GN, Konstantinidis I, Wyatt CM. HIV and the aging kidney. Curr Opin HIV AIDS. 2014;9(4):340\u20135.","journal-title":"Curr Opin HIV AIDS"},{"issue":"5","key":"1659_CR3","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/1744-9987.12675","volume":"22","author":"M Urata","year":"2018","unstructured":"Urata M, Narita Y, Fukunaga M, et al. Simple formula for predicting drug removal rates during hemodialysis. Ther Apher Dial. 2018;22(5):485\u201393.","journal-title":"Ther Apher Dial"},{"key":"1659_CR4","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.4009\/jsdt.37.1893","volume":"37","author":"S Hirata","year":"2004","unstructured":"Hirata S, Izumi S, Furukubo T, et al. Factors influencing the removal rate of drugs by hemodialysis. J Jpn Soc Dial Ther. 2004;37:1893\u2013900.","journal-title":"J Jpn Soc Dial Ther"},{"issue":"4","key":"1659_CR5","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1128\/AAC.03131-15","volume":"60","author":"J Molto","year":"2016","unstructured":"Molto J, Graterol F, Miranda C, et al. Removal of dolutegravir by hemodialysis in HIV-infected patients with end-stage renal disease. Antimicrob Agents Chemother. 2016;60(4):2564\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"1659_CR6","doi-asserted-by":"publisher","first-page":"e0203890","DOI":"10.1371\/journal.pone.0203890","volume":"13","author":"D Ware","year":"2018","unstructured":"Ware D, Palella FJ Jr, Chew KW, et al. Prevalence and trends of polypharmacy among HIV-positive and negative men in the multicenter AIDS cohort study from 2004 to 2016. PLoS One. 2018;13(9):e0203890.","journal-title":"PLoS One"},{"issue":"4","key":"1659_CR7","first-page":"163","volume":"42","author":"M N\u00fa\u00f1ez-N\u00fa\u00f1ez","year":"2018","unstructured":"N\u00fa\u00f1ez-N\u00fa\u00f1ez M, Casta\u00f1eda-Mac\u00edas I, Sandoval-Fern\u00e1ndez Del Castillo S. Potential interactions in a cohort of elderly hiv-positive patients. Farm Hosp. 2018;42(4):163\u20137.","journal-title":"Farm Hosp"},{"key":"1659_CR8","unstructured":"Ambrisentan (Letairis) prescribing information. Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/022081s033lbl.pdf."},{"key":"1659_CR9","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/ki.2013.186","volume":"84","author":"ME Sise","year":"2013","unstructured":"Sise ME, Courtwright AM, Channick RN. Pulmonary hypertension in patients with chronic and end-stage kidney disease. Kidney Int. 2013;84:682\u201392.","journal-title":"Kidney Int"},{"key":"1659_CR10","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.jpba.2017.05.052","volume":"143","author":"Y Enderle","year":"2017","unstructured":"Enderle Y, Witt L, Wilkens H, et al. Simultaneous quantification of endothelin receptors antagonists and phosphodiesterase 5 inhibitors currently used in pulmonary artery hypertension. J Pharm Biomed Anal. 2017;143:291\u20138.","journal-title":"J Pharm Biomed Anal"},{"issue":"2","key":"1659_CR11","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3851\/IMP1506","volume":"15","author":"J Dingemanse","year":"2010","unstructured":"Dingemanse J, van Giersbergen PL, Patat A, Nilsson PN. Mutual pharmacokinetic interactions between bosentan and lopinavir\/ritonavir in healthy participants. Antivir Ther. 2010;15(2):157\u201363.","journal-title":"Antivir Ther"},{"key":"1659_CR12","unstructured":"Bosentan Tracleer prescribing information. Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209279s000lbl.pdf."},{"issue":"3","key":"1659_CR13","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1093\/jac\/dkx459","volume":"73","author":"J Molt\u00f3","year":"2018","unstructured":"Molt\u00f3 J, Curran A, Miranda C, et al. Pharmacokinetics of darunavir\/cobicistat and etravirine alone and co-administered in HIV-infected patients. J Antimicrob Chemother. 2018;73(3):732\u20137.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"1659_CR14","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1007\/s00228-013-1529-1","volume":"69","author":"C Markert","year":"2013","unstructured":"Markert C, Hellwig R, Burhenne J, et al. Interaction of ambrisentan with clarithromycin and its modulation by polymorphic SLCO1B1. Eur J Clin Pharmacol. 2013;69(10):1785\u201393.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"1659_CR15","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/bcpt.12332","volume":"116","author":"C Markert","year":"2015","unstructured":"Markert C, Kastner IM, Hellwig R, et al. The effect of induction of CYP3A4 by St John\u2019s wort on ambrisentan plasma pharmacokinetics in volunteers of known CYP2C19 genotype. Basic Clin Pharmacol Toxicol. 2015;116(5):423\u20138.","journal-title":"Basic Clin Pharmacol Toxicol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1659-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-019-1659-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1659-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T00:08:41Z","timestamp":1611706121000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-019-1659-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,28]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1659"],"URL":"https:\/\/doi.org\/10.1186\/s12882-019-1659-5","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,28]]},"assertion":[{"value":"1 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not Applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this Case Report and any accompanying images and videos. A copy of the written consent is available for review by the Editor of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"WEH reports having received personal fees, non-financial support, or other support such as research grants from Actelion GmbH, Aspen Europe GmbH, AstraZenica GmbH, BayerPharma AG, Berlin-Chemie AG, Boehringer GmbH, GSK, Bristol-Myers Squibb GmbH, Chiesi GmbH, Daiichi Sankyo GmbH, MSD Sharp & Dohme GmbH, Roche, Gr\u00fcnenthal GmbH, Novartis, Pfizer GmbH, and personal fees and other from Roche GmbH, Smooth ClinicalTrials Ltd., Sumaya Biotec GmbH & Co. KG, and Vaximm GmbH. JRS and JM have received research funding, consultancy fees, and lecture sponsorships from and have served on advisory boards for various laboratories (MSD, Abbvie, Boehringer Ingelheim, Gilead Sciences, Viiv Healthcare, Janssen Cilag, and Bristol-Myers-Squibb).AM, CM, MP, LB, and IB have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing of interests"}}],"article-number":"24"}}